Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Europe
  • Middle East & Africa
  • Asia Pacific
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Latin America | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Europe Middle East & Africa Asia Pacific
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latin America | es
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About
      • Board of Directors
        • Joerg Reinhardt
        • Simon Moroney
        • Nancy Andrews
        • Ton Buechner
        • Patrice Bula
        • Elizabeth Doherty
        • Ana de Pro Gonzalo
        • Bridgette Heller
        • Daniel Hochstrasser
        • Frans van Houten
        • Andreas von Planta
        • Charles Sawyers
        • William Winters
        • Charlotte Pamer-Wieser
      • Executive Committee
        • Vasant Narasimhan
        • Shreeram Aradhye, M.D.
        • James Bradner
        • Victor Bulto
        • Karen Hale
        • Harry Kirsch
        • Rob Kowalski
        • Steffen Lang
        • Klaus Moosmayer
        • Richard Saynor
        • Marie-France Tschudin
        • Lutz Hegemann
        • Michael Willi
        • Kees Roks
      • Strategy
        • People and Culture
        • Data and Digital
      • Products
      • Innovative Medicines
      • Sandoz
      • Operations
        • Global Biotech Cooperations
      • Diversity & Inclusion
        • Equity
        • Diversity & Inclusion Governance and Community
        • Inclusivity
        • Parental Leave
        • Society
      • Quality
        • Audit program
        • Novartis Quality Management System (QMS)
        • Product and patient safety training
        • Regulatory inspections
        • Product recalls
        • Third-party suppliers
      About Novartis
    • Patients and Caregivers
      • Novartis Commitment to Patients and Caregivers
      • Diseases
      • Patient Organization Funding
      • Adverse Event Reporting
      • COVID-19: Patients and Caregivers
      • Stories: Patients Perspectives
      Patients & Caregivers
    • Healthcare Professionals
      • Medical Congresses and Events
        • Abstract summaries for EULAR
        • Abstract summaries for ACR
        • Abstract summaries for EADV
      • Products
      • Novartis Pipeline
      • Managed Access Programs
        • Novartis Gene Therapies Managed Access Program
      • Novartis External Funding
      • Healthcare Professional Resources by Country
      • Investigator-Initiated Trials / Studies
      • Transparency and Disclosure
      Healthcare Professionals
    • Research & Development
      • Novartis Institutes for BioMedical Research
        • Collaborations
        • NIBR Global Scholars Program
      • Technology Platforms
        • Radioligand Therapy
        • Gene Therapy
        • Cell Therapy
      • Research Disease Areas
        • Immuno-oncology research at Novartis
        • Oncology research at Novartis
        • Cardiovascular and metabolic disease research at Novartis
        • Autoimmunity, transplantation and inflammatory disease research at Novartis
        • Ophthalmology research at Novartis
        • Neuroscience Research at Novartis
        • Musculoskeletal Disease Research at Novartis
        • DAx: exploratory disease research at Novartis
      • Research Locations
        • Novartis Institute for Tropical Diseases
      • Novartis Pipeline
      • Translational Medicine
      • Research & Development Approach
      • Stories from our Labs
      • Open Source Science
      Research & Development
    • ESG
      • Access
        • Creating sustainable business models
        • Value-Based Pricing
        • Sub-Saharan Africa
        • Donations
        • Novartis Access Principles
        • Novartis Oncology Access
        • Patents and Licensing
      • Ethics, Risk and Compliance
        • Ethical Behavior
        • Compliance
        • Human Rights
        • Learning and Engagement
        • Risk management
      • Environmental Sustainability
        • Climate
        • Waste
        • Water
      • Global Health
        • Anti-Microbial Resistance (AMR)
        • Avoidable Blindness
        • Chagas Disease
        • Leprosy
        • Malaria
        • Sickle Cell Disease (SCD)
        • Novartis Foundation
      • Diversity & Inclusion
      • Reporting
        • Environmental, Social and Governance (ESG) Index
        • ESG Rating Performance
        • Codes, Policies and Guidelines
        • Materiality Assessment
        • Transparency and Disclosure
        • Targets
        • Positions
      Environmental, Social and Governance
    • Investors
      • Event Calendar
      • Financial Data
        • Novartis Annual Results
        • Novartis Quarterly Results
        • Novartis SEC Filings
        • Product Sales
        • Fixed-Income Securities
        • Expected Currency Impact
      • Share Data & Analysis
        • Share Monitor
        • Dividend Information
        • Share Ownership
        • Share Overview
      • Shareholder Information
        • General Meetings
        • American Depository Receipts (ADR)
        • Share Buy-Back
        • Frequently Asked Questions
      • Company Overview
        • Corporate Governance
      • Novartis Annual Reporting Suite
        • Reporting Archive
        • Publications Order Form
      • ESG
      Investors
    • News
      • News Archive
      • Media Library
      • Stories
      • Subscribe
      News
    • Careers
      • Career Search
      • Our Teams
        • Careers in Commercial
        • Careers in Communications and Advocacy
        • Careers in Consulting
        • Careers in Digital
        • Careers in Health, Safety & Environment
        • Careers in Information Technology (IT)
        • Careers in Medical & Development
        • Careers in People & Organization
        • Careers in Procurement
        • Careers in Research
        • Careers in Strategy
        • Careers in Manufacturing and Supply
        • Ethics, Risk & Compliance (ERC)
        • Careers in Legal
      • Career Programs
        • Community Exploration & Learning Lab (CELL)
      • Early Talent
      • Postdoc Program
        • Andreas Bender, PhD
        • Boxun Lu, PhD
        • The Novartis Innovation Postdoctoral Fellowship
        • The Novartis Discovery Postdoctoral Fellowship
        • Postdoc Research Themes
        • Recognition
        • Postdoc Program Leadership
      • International Careers
      • Learning and Development
      • Well-being
      • Internship Programs
      Careers
    • COVID-19 Information Center
      COVID-19 Novartis response
    • Clinical Trials
      Clinical Trials
    • Partnering
      Partnering
    • Contacts
      Contacts
    Home
  • Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
    Basel, March 10, 2022 — Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.
    Global Health PartnershipsCell and Gene TherapyCancer
  • Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine
    Basel, October 21, 2021 — Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities to address the COVID-19 pandemic by expanding its support of the fill and finish of the Pfizer-BioNTech COVID-19 vaccine. Novartis will use its sterile manufacturing facilities at its Novartis Technical…
    Global Health PartnershipsDisease AwarenessAccess to Healthcare
  • Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
    Basel, June 23, 2021 — Novartis and Hewlett Packard Enterprise (HPE) today announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to healthcare and medicines.
    Novartis AccessGlobal Health PartnershipsFuture of HealthcareAccess to Healthcare
  • Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity
    Basel, July 20, 2021 — Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs) to co-create programs that address the…
    Social CommitmentGlobal Health PartnershipsFuture of HealthcareEthical Business
  • Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
    Basel, October 28, 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423. The collaboration aims to leverage Molecular Partners’…
    Reimagine MedicineInfectious DiseasesGlobal Health PartnershipsBiomedical Research
  • Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
    Basel, February 25, 2020 – Novartis and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world’s leading parasitic killers.
    Global Health PartnershipsAfricaAccess to Healthcare
  • Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
    Basel, April 2, 2020 — Novartis today announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-191-3.
    Social CommitmentInfectious DiseasesGlobal Health Partnerships
  • Access to Healthcare
    Partnering for improved cancer care around the globe

    Novartis works tirelessly with third-party organizations to improve access to cancer care.

    Access to HealthcareAfricaGlobal Health PartnershipsNovartis Social BusinessOncology
  • Access to Healthcare
    New drugs could offer hope for malaria patients

    In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial.

    Disease EradicationGlobal Health PartnershipsMalariaNovartis Social BusinessPatient EducationTropical Diseases
  • Access to Healthcare
    Making healthcare sustainable in the developing world

    Today, many companies are trying to solve global health challenges through philanthropy. However, it has become clear that philanthropy alone is no longer enough to make a lasting impact.

    Access to HealthcareFuture of HealthcareGlobal Health PartnershipsNovartis Social BusinessSustainable Development
  • Patient Perspectives
    Conversations with Patient Advocates: Ron Hollander, president of INCA

    Ron Hollander, president of the International Neuroendocrine Cancer Alliance, talks to us about patient advocacy.

    CancerDisease AwarenessGlobal Health PartnershipsOncologyPatient Voices
  • Access to Healthcare
    Women in Science: Fionnuala Doyle

    Doyle describes the road to improving patient outcomes across Europe through the HARMONY Alliance.

    CancerDigitalGlobal Health PartnershipsOncologyWomen in ScienceWorking at Novartis

Pagination

  • 1
  • 2
  • › Next page

Novartis

Navigate
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • COVID-19 Info Center
  • ESG
Explore
  • Stories
  • Diseases
  • Locations
  • Products
  • Novartis Pipeline
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2022 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience